Week in Review: Vivace Details its Capital Efficient Plan to Develop Novel Cancer Therapies

Company Spotlight - In an exclusive interview, Sofie Qiao, PhD, President/CEO of Vivace Therapeutics, discussed the novel science behind Vivace's portfolio and the company's US-China capital-efficient business plan; Deals and Financings - Seattle's Rodeo Therapeutics announced a $5.9 million financing, including participation by WuXi AppTec, for small-molecule therapies to promote tissue repair; - Nanjing Frontier Biotechnologies acquired global rights to a novel broad-spectrum HIV neutralizing antibody from Rockefeller University of the US; Industry Insights - We list and profile the top 10 China pharma companies ranked by a combination of each company's revenues and market capitalization; Trials and Approvals - The CFDA approved a superficial radiation therapy device made by Sensus Healthcare of the US to treat and prevent keloids; - DelMar Pharma, a Canada-US biopharma, was approved to start a China Phase II trial of its lead candidate, which targets glioblastoma multiforme. Stock Symbols: (NSDQ: SRTS) (NSDQ: DMPI) Share this with colleagues: // //